Rna replicon for improving gene expression and use thereof
US-2024417751-A1 · Dec 19, 2024 · US
Pharmaceutical composition for preventing and treating cancer, containing CYB5R3 gene or protein as active ingredient
US10973884B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10973884-B2 |
| Application number | US-201615087563-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2016 |
| Priority date | Oct 1, 2013 |
| Publication date | Apr 13, 2021 |
| Grant date | Apr 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1α (HIF-1α) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating cancer comprising a step of administering a vector containing a polynucleotide encoding cytochrome b5 reductase 3 (CYB5R3) protein or a cell containing the vector to a subject in need of cancer treatment; wherein the CYB5R3 protein is overexpressed and inhibits hypoxia-inducible factor 1 (HIF-1) in cancer cells of the subject, and wherein the cancer is one or more cancers selected from the group consisting of colorectal cancer, liver cancer, stomach cancer, breast cancer, pancreatic cancer, prostate cancer, lung cancer, and kidney cancer. 2. The method for treating cancer according to claim 1 , wherein the CYB5R3 protein consists of the amino acid sequence represented by SEQ. ID. NO: 1 (GenBank Accession No: AAH04821). 3. The method for treating cancer according to claim 1 , wherein the vector is a linear DNA, a plasmid DNA, or a recombinant virus vector. 4. The method for treating cancer according to claim 3 , wherein the recombinant virus is selected from the group consisting of native or modified form of retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, vaccinia virus. 5. The method for treating cancer according to claim 1 , wherein the cell is selected from the group consisting of hematopoietic stem cells, dendritic cells, autologous tumor cells, and established tumor cells.
Assignees
Inventors
Classifications
involving compounds localised on the membrane of tumour or cancer cells · CPC title
Cytochrome-b5 reductase (1.6.2.2) · CPC title
characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title
- A61K48/00Primary
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10973884B2 cover?
- The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1α (HIF-1α) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the …
- Who is the assignee on this patent?
- Korea Res Inst Bioscience & Biotechnology
- What technology area does this patent fall under?
- Primary CPC classification A61K48/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).